The Plot Twist Nobody Expected
If you've ever started a GLP-1 medication like Ozempic, Wegovy, or Mounjaro and then stopped—you're definitely not alone. And according to fresh research presented at ENDO 2026, the idea that most people stay on these medications long-term might be a bit of a myth.
Here's what the study found: out of more than 60,000 Americans with type 2 diabetes taking these drugs, about 4 out of 10 stopped within the first year. By year two? Nearly 6 out of 10 had called it quits.
But here's where it gets interesting.
"I'm Not Done With You, Doc"
The researchers discovered something that totally flips the script on how we think about GLP-1 discontinuation. Of those who stopped, more than half restarted within a year, and nearly two-thirds came back within two years.
This isn't people abandoning treatment. It's more like... hitting pause.
Think about it. Maybe someone's dealing with side effects and needs a break. Maybe they hit a goal and felt ready to manage on their own for a while. Maybe life just got complicated. But eventually, many of them circled back.
"We didn't see abandonment," the researchers essentially concluded. "We saw a pattern of stopping and starting that's more normal than anyone realized."
Who's More Likely to Hit Pause?
The study also looked at who tends to stop and why. A few patterns emerged:
Demographics played a role. People on Medicaid or Medicare, as well as Black patients, were more likely to discontinue treatment. This raises important questions about access, support systems, and whether everyone has equal footing when it comes to staying the course.
Side effects mattered—a lot. About 37% of people who experienced nausea or other stomach issues stopped within the first year. Honestly, if you've ever dealt with that kind of GI distress, this number makes total sense.
The doctor made a difference. Patients whose first prescription came from an endocrinologist (a hormone specialist) were 10% less likely to quit. Makes you wonder: are specialists better at setting expectations? Providing support? Both?
Newer meds won the persistence game. People on tirzepatide (Mounjaro) were 41% less likely to stop compared to those on older medications like liraglutide (Victoza). Semaglutide users were 28% less likely to quit than the older drug group. Newer formulations might simply be easier to tolerate, or maybe they work better—either way, the data is pretty compelling.
Why Staying on Track Actually Matters
Here's where I want to get a little serious. These medications aren't just about losing weight or lowering blood sugar numbers on a chart. They're doing real, important work inside your body—protecting your heart, slowing kidney disease progression, reducing inflammation.
When you stop taking them, you're potentially giving up those protective benefits. The researchers put it plainly: "Stopping early may mean missed opportunities to prevent heart attacks, kidney disease progression and other complications."
That's not meant to scare you. It's meant to underscore why those conversations with your doctor about why you want to stop matter so much. If side effects are the culprit, maybe there's a workaround. If cost is the issue, maybe there are assistance programs. If you just feel ready to try life without them—well, that's worth discussing too.
The Bigger Picture
What I find most valuable about this research is what it tells us about the real-world journey with these medications. Clinical trials show beautiful adherence rates. But real life? Real life is messier. People take breaks. Life happens. Bodies react.
This doesn't mean GLP-1 medications don't work. It means they're being used in a more nuanced, human way than we initially understood.
For healthcare providers, this research is a call to check in—not just when patients refill, but when they don't refill. For insurers, it's a reminder that covering restart periods matters. And for patients? It's permission to be honest about when things aren't going perfectly.
The start-stop pattern isn't a failure. For many people, it might just be part of the process.
What do you think? Have you or someone you know taken a break from GLP-1 therapy? I'd love to hear about it in the comments—let's talk through this together.